Literature DB >> 18231751

Reversal of multidrug resistance and inhibition of phosphorylation of AKT in human ovarian cancer cell line by wild-type PTEN gene.

Huijuan Wu1, Danhui Weng, Hui Xing.   

Abstract

The reversing effect of wild-type PTEN gene on resistance of C13K cells to cisplatin and its inhibitory effect on the phosphorylation of protein kinase B (AKT) were studied. The expression of PTEN mRNA and protein in OV2008 cells and C13K cells were semi-quantitatively detected by using RT-PCR and Western blotting. Recombinant eukaryotic expression plasmid containing human wild-type PTEN gene was transfected into C13K cells by lipofectamine2000. The expression of PTEN mRNA was monitored by RT-PCR and the expression of PTEN, Akt, p-Akt protein were analyzed by Western blotting in PTEN-transfected and non-transfected C13K cells. Proliferation and chemosensitivity of cells to DDP were measured by MTT, and cell apoptosis was detected by flow cytometry after treatment with cisplatin. The expression of PTEN mRNA and protein in OV2008 cells were significantly higher than those in C13K cells. After transfection with PTEN gene for 48 h, the expression of PTEN mRNA and protein in C13K cells were 2.04 +/- 0.10, 0.94 +/- 0.04 respectively and the expression of p-Akt protein (0.94 +/- 0.07) was lower than those in control groups (1.68 +/- 0.14, 1.66 +/- 0.10) (P < 0.05). The IC(50) of DDP to C13K cells transfected with PTEN (7.2 +/- 0.3 micromol/L) was obviously lower than those of empty-vector transfected cells and non-transfected cells (12.7 +/- 0.4 micromol/l, 13.0 +/- 0.3 micromol/L) (P<0.05). The apopototis ratio of wild-type PTEN-transfected, empty vector transfected and non-transfected C13K cells were (41.65 +/- 0.87)%, (18.61 +/- 0.70)% and (15.28 +/- 0.80)% respectively, and the difference was statistically significant (P<0.05). PTEN gene plays an important role in ovarian cancer multidrug resistance. Transfection of PTEN could increase the expression of PTEN and restore drug sensitivity to cisplatin in human ovarian cancer cell line C13K with multidrug-resistance by decreasing the expression of p-Akt.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18231751     DOI: 10.1007/s11596-007-0625-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

Review 1.  The multiple roles of PTEN in tumor suppression.

Authors:  A Di Cristofano; P P Pandolfi
Journal:  Cell       Date:  2000-02-18       Impact factor: 41.582

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 3.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

Authors:  Sooyong Lee; Eui-Ju Choi; Changbae Jin; Dong-Hyun Kim
Journal:  Gynecol Oncol       Date:  2005-04       Impact factor: 5.482

5.  Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN.

Authors:  T Schöndorf; M Becker; U J Göhring; B Wappenschmidt; H Kolhagen; C M Kurbacher
Journal:  Anticancer Drugs       Date:  2001-11       Impact factor: 2.248

6.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  AKT involvement in cisplatin chemoresistance of human uterine cancer cells.

Authors:  Véronique Gagnon; Isabelle Mathieu; Emilie Sexton; Kim Leblanc; Eric Asselin
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

9.  Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.

Authors:  Xiaojuan Yan; Michael Fraser; Qing Qiu; Benjamin K Tsang
Journal:  Gynecol Oncol       Date:  2006-03-20       Impact factor: 5.482

10.  In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.

Authors:  M Tanaka; H B Grossman
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.